Quest Pharmatech Inc V.QPT

Alternate Symbol(s): QPTFF

Healthcare Biotechnology

Quest PharmaTech Inc. is a Canadian biopharmaceutical company. The Company is developing products to improve the quality of life. It is developing the proprietary, MAb-AR9.6, targeting MUC16 as a diagnostic agent for cancer. MAb-AR9.6 is licensed from the University of Nebraska Medical Centre and is in late preclinical stage development. The Company has a 42.5% ownership interest in OncoQuest Inc., which is a biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest Inc.’s technology platform includes a panel of tumor antigen specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent, which is developing antibody-based immunotherapeutic products for cancer in the Greater China territory.

TSXV:QPT - Post by User

Quest Pharmatech Inc

<< Previous

Bullboard Posts

Next >>

(258)
•••

Comment by G1945Von Sep 23, 2023 7:42am

75 Views

Post# 35650512

RE:RE:Interesting

"The cash is receivable in 3 tranches (immediately – 21.6 billion KRW ($22,291,000), end of December 2023 – 25.9 billion KRW ($26,728,600) and end of June 2024 – 30.0 billion KRW ($30,959,800))."

Are we missing the date of the third tranche in the amount of $30,959,800?

G1945V

<< Previous

Bullboard Posts

Next >>

Clearmind posts results from cocaine addiction treatment